Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 10.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 114,035 shares of the medical instruments supplier’s stock after purchasing an additional 10,553 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Becton, Dickinson and were worth $28,534,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in Becton, Dickinson and in the 3rd quarter valued at about $1,169,000. Flagship Private Wealth LLC acquired a new stake in Becton, Dickinson and in the 4th quarter valued at about $25,000. Simon Quick Advisors LLC raised its position in shares of Becton, Dickinson and by 1,657.1% during the 3rd quarter. Simon Quick Advisors LLC now owns 123 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 116 shares in the last quarter. Dimension Capital Management LLC acquired a new stake in shares of Becton, Dickinson and during the 3rd quarter worth about $29,000. Finally, Mcmillion Capital Management Inc. acquired a new stake in shares of Becton, Dickinson and during the 4th quarter worth about $40,000. 83.22% of the stock is currently owned by institutional investors.
Several equities research analysts have recently weighed in on the company. Piper Sandler raised their target price on Becton, Dickinson and from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 4th. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price target on the stock. in a research note on Wednesday, January 13th. Raymond James raised their price target on Becton, Dickinson and from $270.00 to $282.00 and gave the stock an “outperform” rating in a research note on Friday, January 29th. The Goldman Sachs Group downgraded Becton, Dickinson and from a “conviction-buy” rating to a “buy” rating in a research note on Tuesday, December 15th. Finally, TheStreet upgraded Becton, Dickinson and from a “c+” rating to an “a-” rating in a research note on Thursday, February 4th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $281.08.
Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The firm had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the previous year, the firm posted $2.65 earnings per share. Becton, Dickinson and’s revenue was up 25.8% on a year-over-year basis. As a group, equities research analysts predict that Becton, Dickinson and Company will post 12.5 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 31st. Stockholders of record on Wednesday, March 10th will be issued a $0.83 dividend. The ex-dividend date of this dividend is Tuesday, March 9th. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.35%. Becton, Dickinson and’s dividend payout ratio (DPR) is 32.55%.
Becton, Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Insider Trading
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.